Meanwhile, weight loss achieved with GLP-1s is gradual and sustainable, creating long-term benefits for overall wellness
GLP-1 medications may be HSA/FSA eligible benefits, depending on your coverage and plan
Int J Cardiol 1(418):132611
In a Clinical review for semaglutide, the incidence of acute pancreatitis was found to occur more frequently in GLP1 users compared to placebo
According to the results of the RCT for patients with monogenic obesity ( LEPR or POMC deficiency) and acquired hypothalamic obesity, setmelanotide can reduce body weight and inhibit appetite to a certain extent, and common adverse reactions include injection site reactions, skin hyperpigmentation, nausea, diarrhea, and abdominal pain, with occasional occurrences of sexual adverse reactions, depression, and suicidal ideation [51,52]
For example, studies on semaglutide 2.4 mg daily reveal an average 8% weight loss in individuals with diabetes over 60 weeks, while those without diabetes see closer to 11%
